Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.38 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930316 | 1.00 | MYC (0.40) | MYCKDM4EALDH1A1GAATHRB | |
| SCHEMBL29082603 | 0.83 | MAP3K7 (0.40) | KDM4EALDH1A1GAATHRBATM | |
| SCHEMBL4144972 | 0.83 | THRB (0.38) | KDM4EALDH1A1GAATHRBATM | |
| SCHEMBL4144963 | 0.83 | THRB (0.38) | KDM4EALDH1A1GAATHRBATM | |
| SCHEMBL12408963 | 0.78 | QPCT (0.38) | MYCKDM4EALDH1A1PLAUACACB | |
| SCHEMBL4082657 | 0.77 | QPCT (0.38) | MYCGAAPLAUACACBQPCT | |
| SCHEMBL8966682 | 0.77 | QPCT (0.38) | MYCGAAKMT2APLAUACACB | |
| SCHEMBL8966684 | 0.77 | QPCT (0.38) | MYCGAAKMT2APLAUACACB | |
| SCHEMBL4082660 | 0.77 | QPCT (0.38) | MYCGAAPLAUACACBQPCT | |
| SCHEMBL1904655 | 0.76 | QPCT (0.39) | MYCKDM4EALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| EP-1185869-B1 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | GRAFFINITY PHARMACEUTICALS AG (DE) | 2006-07-26 | — | — | EP | disclosed |
| US-20050153357-A1 | Bioactive sensors | EICHLER JUTTA (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020127577-A1 | Bioactive sensors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-09-12 | — | — | US | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-5521163-A | TREATMENT OF HERPES VIRUS WITH 1'-DEOXY-5-ETHYL-4'-THIO-BETA URIDINE | UNIVERSITY OF BIRMINGHAM (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0421777-B1 | Further antiviral pyrimidine nucleosides | UNIV BIRMINGHAM (GB) | 1996-02-28 | — | — | EP | disclosed |
| EP-0658166-A1 | ANTIVIRAL PYRIMIDINE NUCLEOSIDES | THE UNIVERSITY OF BIRMINGHAM (GB) | 1995-06-21 | — | — | EP | disclosed |
| US-5356882-A | Treating herpes virus | UNIVERSITY OF BIRMINGHAM (GB) | 1994-10-18 | — | — | US | disclosed |
| WO-1994005687-A1 | ANTIVIRAL PYRIMIDINE NUCLEOSIDES | UNIVERSITY OF BIRMINGHAM (GB) | 1994-03-17 | — | — | WO | disclosed |
| EP-0421777-A1 | Further antiviral pyrimidine nucleosides | THE UNIVERSITY OF BIRMINGHAM (GB) | 1991-04-10 | — | — | EP | disclosed |
| WO-1991001326-A1 | ANTIVIRAL PYRIMIDINE NUCLEOSIDES | UNIVERSITY OF BIRMINGHAM (GB) | 1991-02-07 | — | — | WO | disclosed |
| EP-0409575-A1 | Antiviral pyrimidine nucleosides | THE UNIVERSITY OF BIRMINGHAM (GB) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | MYC 3154/4885KDM4E 3977/4885ALDH1A1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.